Dynavax Technologies Corporation news

   Watch this stock
Showing stories 11 - 20 of about 91   

Articles published

DVAX 17.10 0.00 (0.00%)
price chart
Dynavax Technologies (DVAX) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Dynavax Technologies Corporation (DVAX - Snapshot Report).
Zacks: Analysts Set $28.33 Target Price for Dynavax Technologies (NASDAQ ...
Analysts have set a twelve-month consensus price target of $28.33 for the company and are predicting that the company will post ($1.07) earnings per share for the current quarter, according to Zacks. Zacks has also given Dynavax Technologies an ...
Stocks Underperform for the Week: William Lyon Homes , Dynavax ...  Ashburn Daily
Mid-Day Changers: Dynavax Technologies Corporation (DVAX), Gladstone ...  WallStreet Scope
Bullish and Outperform S&P 500: Gartner Inc , Dynavax Technologies Corporation
Shares of Gartner Inc (NYSE:IT) appreciated by 0.98% during the past week but lost 2.99% on a 4-week basis. The shares have outperformed the S&P 500 by 2.24% in the past week but underperformed the index by 0.53% in the past 4 weeks.
Dynavax Technologies Receives Consensus Recommendation of "Strong Buy ...
Dynavax Technologies logo Shares of Dynavax Technologies (NASDAQ:DVAX) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports.
Dynavax: A Takeover Target?
With the announcement by the company that the FDA sent them a Complete Response Letter (NYSE:CRL), the stock once again was sent tumbling, this time below $2, before recovering to close just above that level Monday and Tuesday of this week.
Related articles »  
Dynavax Technologies Q2 Loss Wider than Expected, Sales Beat
Dynavax Technologies Corporation (DVAX - Snapshot Report) reported a loss of 9 cents per share in the second quarter of 2014, flat with the year-ago quarter but wider than the Zacks Consensus Estimate of a loss of 6 cents.
Related articles »  
Dynavax: Assembling The A-Team
As I noted earlier this year, on Thursday, March 21, 2013, Dynavax Technologies Corporation (NASDAQ:DVAX) announced that David Novack joined the company as its Senior Vice President, Operations and Quality, effective March 25, 2013.
Related articles »  
Hedge Funds Are Crazy About Dynavax Technologies Corporation (DVAX)
Dynavax Technologies Corporation To the average investor, there are dozens of gauges shareholders can use to track publicly traded companies.
Dynavax: FDA Asks For Additional Safety Data  Seeking Alpha
Dynavax's hepatitis B vaccine delayed as FDA seeks more data  Reuters
Related articles »  
Dynavax Technologies Corporation (DVAX) news: Dynavax drops request for ...
Dynavax (DVAX +1.7%) withdraws its application for the European approval of the company's Hepatitis B vaccine Heplisav after the European Medicines Agency (EMA) indicated that the product's safety database is too small to rule out the risk of less ...
Dynavax Withdraws MAA on Heplisav - Analyst Blog  NASDAQ
Dynavax Withdraws MAA on Heplisav  Zacks.com
Related articles »  
Wednesday Stocks to Watch: Dynavax Technologies Corp , CBRE Clarion ...
Dynavax Technologies Corp (DVAX) shed 0.3 points or 1.6304% in the trading session. The share began trading at 18.19 per piece but could only manage 18.72 on the higher end before succumbing to pressure which brought the price down to close at 18.1.